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Rome, Rome, Italy
Testicular cancer (TC) is one of the most treatable of all malignancies and the
management of the quality of life of these patients is increasingly important, especially
with regard to their sexuality and fertility. Survivors must overcome anxiety and fears
about reduced fertility and possible pregnancy-related risks as well as health effects in
offspring. There is thus a growing awareness of the need for reproductive counseling
of cancer survivors. Studies found a high level of sperm DNA damage in TC patients
in comparison with healthy, fertile controls, but no significant difference between these
patients and infertile patients. Sperm DNA alterations due to cancer treatment persist
from 2 to 5 years after the end of the treatment and may be influenced by both the
type of therapy and the stage of the disease. Population studies reported a slightly
reduced overall fertility of TC survivors and a more frequent use of ART than the general
population, with a success rate of around 50%. Paternity after a diagnosis of cancer is
an important issue and reproductive potential is becoming a major quality of life factor.
Sperm chromatin instability associated with genome instability is the most important
reproductive side effect related to the malignancy or its treatment. Studies investigating
the magnitude of this damage could have a considerable translational importance in the
management of cancer patients, as they could identify the time needed for the germ
cell line to repair nuclear damage and thus produce gametes with a reduced risk for the
offspring.
Keywords: sperm DNA damage, sperm chromatin, testicular cancer, reproductive outcome, fatherhood, cancer
survivors
INTRODUCTION
Spermatogenesis is the process through which undifferentiated stem cells proliferate and
differentiate into spermatozoa. It takes place in the seminiferous tubules in the testicles and
is classically divided into three stages: spermatogonial proliferation, meiosis, and spermiogenesis
(1, 2).
The mature spermatozoon’s main function is to transfer the undamaged haploid genome to
the oocyte. During the spermatogenetic process the protection of DNA is thus of considerable
importance, and it is kept safe through its sperm-specific packaging (3). This is made
possible by the binding of DNA with protamines (4–11), which collapse into a toroidal
structure and anchor to matrix-associated regions (12–14). Correct DNA-matrix structure is
required to replicate male pronuclear DNA and control nuclear integrity after fertilization,
since the nuclear matrix plays a pivotal role (15–17). This specific chromatin organization
is associated with the recruitment, integrity and function of DNA repair components (18).
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DNA strand breaks may occur as a natural consequence of
chromatin reorganization, and sperm with highly condensed
chromatin may also suffer damage. This process begins in the
nuclear matrix. The action of external nucleases causes DNA
to be degraded and released by this structural scaffold (19,
20). The DNA fragmentation process begins during epididymal
maturation and transit through the vas deferens. The luminal
fluid contains enzymes which act like nucleases, activating
an apoptosis-like mechanism that in turn triggers sperm self-
destruction if the sperm cell is damaged for some reason. Various
types of DNA strand breaks have been identified: (a) single-strand
breaks (SSBs) are probably also generated by reactive oxygen
species released from the mitochondria in damaged sperm (21–
23); (b) reversible double-strand breaks (DSBs) are probably
generated by the action of topoisomerase II (19, 24); and (c) non-
reversible DSBs are induced by the action of nucleases that enter
from the luminal fluid (18, 19, 25, 26).
These alterations may be induced by the dysregulation of
normal apoptotic mechanisms and/or by a rise in oxidative stress
due to pathological or iatrogenic factors. The apoptotic process is
a control system for the overproduction of male gametes (27–29)
through which endonucleases induce the formation of double-
strand nicks in the DNA with subsequent DNA degradation,
chromatin condensation and the formation of apoptotic bodies
(30–33).
The sperm cell has three options: (a) repair the damage,
(b) activate the apoptotic process, causing cell death, or (c)
tolerate the damage, resulting in mutations which could be
transmitted to future generations (2, 34, 35). However, mature
sperm are incapable of repairing DNA damage, as translation
and transcription activities are silenced in the later stages of
spermatogenesis (34).
Some authors have shown in animal models that the
spermatocyte can actuate various DSB repair mechanisms (36)
through non-homologous end-joining (NHEJ) and homologous
recombination (HR) (35, 36). These two mechanisms may co-
exist (36–38) but if inadequate, can introduce new mutations.
Despite all this, sperm with fragmented DNA can be fertile,
and the biological impact of an abnormal sperm chromatin
structure depends on the combined effects of the extent of DNA
or chromatin damage in the sperm and the capacity of the oocyte
to repair that damage (35, 39–42).
Clinical Implications
From a clinical perspective, sperm DNA damage, including
chromatin fragmentation, has been associated with impaired
spermatogenesis and infertility and can have negative
consequences on the reproductive process (43–46), including
recurrent pregnancy loss (RPL) (47). Various studies have
investigated the relationship between sperm DNA damage and
reproductive outcome. Studies of natural fertility highlighted
that sperm DNA damage is associated with a prolonged time to
pregnancy (48) as well as a low probability of achieving natural
pregnancy (49). Several studies also reported an association
between low pregnancy rates in ART and DNA damage (50).
Moreover, various authors found a significant correlation
between DNA fragmentation and pregnancy loss after IVF
or ICSI (OR 2.37) (51–53). Available data do not permit any
correlation to be established between chromatin integrity and
reproductive outcome, although there is a significant correlation
between fragmentation and pregnancy loss following IVF or ICSI
(54, 55), as revealed in a meta-analysis (52). Stratification of the
studies by method used to analyse DNA fragmentation produced
different results, with a stronger association found for TUNEL
(53, 56). Most studies using TUNEL reported a significant
impact on embryo development, blastocysts and pregnancy loss
for both IVF and ICSI, whereas studies using SCSA obtained
more variable results (57). This may be because the different
methods identify different aspects of DNA damage: in fact, the
alkaline Comet and TUNEL assays can directly measure the level
of sperm DNA damage, while SCSA indirectly measures the
susceptibility of DNA to damage, consequently influencing the
discovered associations with ART outcome (58, 59).
Different factors, especially leukocytospermia (60, 61),
smoking, obesity and other lifestyles (62–64), age (65, 66), male
accessory gland infections (67), varicocele (68), and neoplastic
diseases (69–72), may be correlated with increased sperm
DNA damage, with a consequent impact on male fertility.
Iatrogenic causes, above all the chemo- and radiotherapies used
to treat cancer, can also have effects on spermatogenesis and
consequently on the sperm chromatin (43, 73, 74) (Figure 1).
Cancer itself also has an important role inmale infertility, with
both direct and indirect effects on spermatogenesis. Particular
attention has been paid to the effects of testicular cancer,
the most common cancer in men of reproductive age (75),
on sperm DNA. The incidence of TC varies considerably in
different countries and in different ethnic groups, possibly in
relation to both environmental factors and genetic susceptibility,
as hypothesized in so-called testicular dysgenesis syndrome
(TDS) (76–80). Various studies have investigated the association
between the presence of persistent environmental pollutants
in serum and the risk of TC, but no strong association has
been identified (81–88). Studies of testicular cancer (70, 71)
revealed impaired sperm chromatin integrity even before any
antineoplastic treatment, with an increase in damaged DNA and
a negative correlation between chromatin damage and semen
quality (69). Despite accounting only for about 1% of all male
cancers, TC was once the main cause of death from cancer in
men of reproductive age, but advances in chemotherapy (CT)
and radiotherapy (RT) combined with surgical techniques have
produced a marked improvement in the prognosis and survival
of these patients (75, 89–92). However, treatment protocols may
have long-term effects including metabolic syndrome, vascular
and cardiac damage, secondary cancers, and infertility (93, 94).
There is also great concern about their effects on semen quality
and sperm chromatin integrity, as the high cell renewal rate
of the seminiferous epithelium makes it highly sensitive to
these treatments (72, 95, 96). The target of any antineoplastic
treatments is DNA, which becomes fragmented, leading to cell
death (72, 95).
To date, there is little literature information on
the damage suffered by sperm DNA after exposure to
antineoplastic treatments. Above all, the duration, extent
and biological significance of their effects on chromatin
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FIGURE 1 | Aetiology and pathogenesis of sperm DNA damage.
integrity and the time necessary to repair such damage
are not yet known. The aim of our paper is to review
the impact of TC and its treatment on the sperm
chromatin quality and reproductive outcome of cancer
survivors following both natural pregnancy and assisted
reproductive technology (ART). This information has
translational relevance for the management and effective
counseling of these patients with regard to their reproductive
potential.
METHODS
We conducted a review of the literature to evaluate the
relationship between testicular cancer, sperm DNA damage
and fertility. We searched the Medline (Pubmed) database
using the following search terms: “sperm DNA damage AND
testicular cancer,” “testicular cancer AND sperm DNA integrity
after therapy,” “assisted reproduction AND testicular cancer,”
“pregnancy outcome AND testicular cancer,” “fatherhood AND
testicular cancer.” Additional studies were identified from the
study reference lists. Only full-length articles published in English
between 1986 and 2018 were searched. With regard to sperm
DNA integrity, we considered only the most common methods
(TUNEL, Comet, SCSA). We found 17 studies that evaluated
pre-therapy sperm DNA integrity in TC patients and 11 that
investigated sperm DNA damage induced by antineoplastic
therapies in such patients. We also found 10 studies derived
from population-based surveys or national cancer registers and
37 suitable studies with information on the outcomes of both
natural and ART-derived pregnancies in TC patients.
CHROMATIN INTEGRITY EVALUATION
Numerous methods have been developed to evaluate sperm
DNA integrity, with the aim of establishing the degree of
chromatin condensation. These tests have been developed in
parallel with advances in ART and the increased understanding
of the importance of chromatin integrity in this context (97). The
most widely used methods for investigating sperm chromatin
integrity in testicular cancer are SCSA, TUNEL and Comet assay.
- SCSA: The sperm chromatin structure assay (SCSA) is a
cytofluorometric technique which indirectly assesses DNA
strand breaks and protamine-histone replacement defects
by measuring the resistance of sperm chromatin to the
action of denaturing agents using the dye acridine orange
(98, 99).
- TUNEL: Terminal deoxynucleotidyl transferase UTP-driven
nick end labeling, or TUNEL, detects the endogenous
DNA strand breaks in sperm through the enzyme TdT
(terminal deoxynucleotidyl transferase). It enables the
incorporation of deoxyuridine triphosphate (dUTP) in DNA
fragments deriving from single or double strand breaks to
be quantified by fluorescence microscopy or cytofluorimetry
(100–102).
- COMET ASSAY: Single cell gel electrophoresis (SCGE),
or Comet assay, enables DNA integrity to be evaluated
by visualizing strand breaks in individual cells (103). The
DNA from the nucleus of any damaged cells forms a
comet pattern with a fluorescent head and a tail whose
length and fluorescence is proportional to the number of
DNA strand breaks. The analysis is performed using a
fluorescence microscope with imaging software. This test
can be performed in both alkaline and neutral conditions:
alkaline Comet reveals both SSBs and DSBs in sperm
DNA, while neutral Comet is capable of selectively detect
DSBs (104). The Comet assay has been used for both the
in vitro evaluation of the mutagenic activity of various
chemicals on sperm (105) and in preliminary studies of
the correlation between fertility and basal sperm DNA
damage (106).
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SPERM DNA DAMAGE IN TESTICULAR
CANCER
Pre-treatment
Evenson et al. were the first to demonstrate abnormal sperm
chromatin condensation, for up to 1 one year post-orchiectomy
and before any antineoplastic treatment, in a study of 14 TC
patients (107). Fossa et al. then found a significant increase in the
percentage of non-condensed haploid sperm cells in 85 testicular
cancer patients post-orchiectomy and pre-treatment compared
with a control group. In the following years, the refinement of
methods to study chromatin integrity led to increasing interest
in sperm DNA damage, especially in testicular cancer, which
involves the sperm production site (108). However, the actual
results are hard to interpret as the available methodologies reveal
different types of nuclear damage.
Although several methods claim to identify “fragmented
DNA,” it is important to understand what each one is actually
measuring. Some tests, such as the alkaline Comet assay
and TUNEL, identify double- and single-strand DNA breaks,
while SCSA assesses the susceptibility of DNA to denaturation,
indirectly revealing possible strand breaks or protamine-histone
replacement defects (98–106).
The theory is that DNA denaturation takes place much more
easily in sites affected by single- or double-strand breaks (109,
110). This information is important in assessing the possibility
of repair, as the oocyte is capable of repairing small numbers of
SSBs, but DSBs may be more problematic (111, 112). Recently,
Comet assay has been performed under neutral condition. This
method could provide more information about the DNA breaks,
although the available evidence is still limited.
It should also be remembered that strand breaks occur
naturally during DNA supercoiling and relaxation (17–19, 23,
26). For this reason, we are presenting the published studies on
the basis of the different methods used to assess sperm chromatin
integrity in testicular cancer.
SCSA
Of the 11 literature reports using this method, seven found sperm
DNA damage in TC patients post-orchiectomy and pre-therapy,
while four did not find any difference between TC patients
and healthy, fertile controls (Table 1). One of the first studies,
dating back to 1997, found abnormal sperm chromatin in a small
caseload of TC patients post-orchiectomy and pre-treatment
compared to healthy semen donors (113). Similar results were
reported by later studies which compared TC to healthy and/or
fertile controls (69, 71, 116, 117, 119, 121) (Table 1). TC patients
showed similar sperm nuclear damage to infertile subjects. Said
et al. in particular found sperm DNA fragmentation levels to be
2-fold higher in TC patients than in healthy fertile controls (117).
Stahl et al. also found greater sperm DNA damage (17.5%) in
TC patients in comparison with a fertile age-matched population
(116). However, the percentage of sperm with fragmented DNA
fell into a moderate level of sperm DNA damage considered
compatible with achieving pregnancy (125). O’Flaherty et al. also
found high mean DFI and low chromatin compaction prior to
chemo/radiotherapy in TC patients in comparison with healthy
TABLE 1 | Studies of sperm DNA damage in testicular cancer patients after
orchiectomy and pre antineoplastic treatment, subdivided by methodology.
References N.
TC pts
Controls Pre-treatment DNA
damage
TC vs. Controls
SCSA
Fossa et al. (113) 39 18 semen donors Increased
Kobayashi et al. (69) 20 12 healthy fertile Increased
Stahl et al. (114) 20 278 military conscripts NOT increased
Stahl et al. (115) 25 278 military conscripts NOT increased
O’Flaherty et al. (71) 15 21 infertile + 21 healthy
volunteers
Increased
Stahl et al. (116) 25 137 healthy fertile Increased
Said et al. (117) 39 20 healthy fertile Increased
Smit et al. (118) 52 22 healthy fertile NOT increased
O’Flaherty et al. (119) 16 11 infertile + 11 healthy
volunteers
Increased vs. healthy
McDowell et al. (120) 37 35 healthy volunteers NOT increased
Bujan et al. (121) 53 257 fertile Increased
Total 341
COMET
O’Donovan et al. (122) 13 14 healthy fertile Increased
O’Flaherty et al. (71) 15 21 infertile + 21 healthy
volunteers
Increased
Kumar et al. (104) 19 20 semen donors Increased
Total 47
TUNEL
Gandini et al. (101) 30 23 healthy + 29 infertile Increased vs. healthy
Spermon et al. (123) 22 13 healthy Increased
Stahl et al. (115) 19 24 military NOT increased
Ribeiro et al. (124) 48 50 healthy fertile NOT increased
O’Flaherty et al. (71) 15 21 infertile + 21 healthy
volunteers
Increased vs. healthy
Bujan et al. (121) 53 257 fertile NOT increased
Total 187
subjects (119). Finally, Bujan et al. found higher levels of DFI in
TC patients than in controls (121).
In contrast, Stahl et al. investigated post-orchiectomy TC
patients prior to further treatment in two studies in 2004 and
2006, finding no differences in the percentage of sperm with
DNA damage between cancer patients and the control group
(114, 115). Smit et al. also found no increase in pre-therapy
DNA damage compared with fertile men. Moreover, sperm DNA
fragmentation does not seem to be correlated with TC histotype:
no significant increase in sperm DNA fragmentation was found
between seminoma and non-seminoma patients (118).McDowell
et al. also failed to find any significant difference in TC patients,
who had a mean of 8.73% sperm DNA damage compared with
the 9.88% seen in men presenting for altruistic sperm donation
(120).
In conclusion, the majority of studies found increased,
but moderate, levels of sperm DNA damage in TC patients
Frontiers in Endocrinology | www.frontiersin.org 4 September 2018 | Volume 9 | Article 506
Paoli et al. Sperm DNA and Testicular Cancer
compared to healthy controls. Infertile patients used as the
control population may have comparable levels of chromatin
damage to TC patients, supporting the hypothesis that TC could
be a cause of temporary infertility by affecting semen quality.
TUNEL
Six studies used TUNEL. Of these, three found more sperm
DNA fragmentation in TC patients while the other three did
not find any differences in chromatin integrity between TC
patients and healthy controls (Table 1). Gandini et al. found
a significant increase in apoptotic sperm DNA fragmentation
in the semen samples of TC patients post-orchiectomy and in
infertile patients with oligoasthenoteratozoospermia compared
with a control group of healthy men (101). This might suggest
that major sperm DNA damage is one of the characteristics of
spermatogenetic failure and that high apoptotic fragmentation is
correlated with impaired semen parameters. In fact, this study
found a negative correlation with sperm motility and a positive
correlation with abnormal forms, predominantly affecting the
head, in TC patients. Increased sperm DNA fragmentation in
TC patients was also confirmed in a study by Spermon et al.
(123). In these patients, neoplastic proliferation seems to induce
intratesticular damage of the apoptosis control system. This
seems to be augmented by the clinical stage of the disease.
O’Flaherty et al. evaluated poor sperm chromatin quality, in
terms of an increase in single- and double-strand breaks and
decrease in the protamine level and chromatin compaction, in
advanced TC patients against control subjects (71). This study
found a non-significant trend increase in TUNEL-positive sperm
in TC patients. Chromatin damage was also found in 37% of
normozoospermic TC patients; interestingly, this damage was
comparable to that seen in the infertile group, as also found in
other studies, demonstrating that TC could be a cause of transient
qualitative sperm damage, even in the absence of significant
quantitative changes.
However, Stahl et al. (115), Ribeiro et al. (124), and Bujan
et al. (121) did not find any correlation between TC and
sperm DNA fragmentation. Stahl et al. (115) investigated
TC patients, finding a similar percentage of sperm DNA
fragmentation to that observed by Gandini et al. (101); the
two studies differed in the control group, which in Gandini’s
study consisted of healthy normozoospermic subjects and in
Stahl’s comprised subjects with various seminal characteristics,
including oligozoospermia. Ribeiro et al. also found no
differences in apoptotic DNA fragmentation between patients
with non-seminoma or seminoma and fertile men (124). The
authors identified a mean of 12.6% sperm cells with apoptotic
DNA fragmentation in the control group, 12.2% in the non-
seminoma group and 12.5% in the seminoma group. In contrast
with the previous studies, the authors suggested that as all
patients were studied after orchiectomy, removal of the affected
testis may have annulled possible effects to the remaining normal
testis. Finally, Bujan et al. evaluated sperm DNA damage in the
semen samples of 53 TC patients, finding no difference in the
percentage of sperm DNA fragmentation between patients and
controls (121).
In conclusion, half of the studies investigating the sperm of
TC patients found an increase in sperm DNA fragmentation,
with the authors suggesting disruption of the apoptotic control
equilibrium as a possible response to the disease. It is possible
that the two studies finding no differences in sperm chromatin
integrity between cases and controls was because they used
control groups with heterogeneous semen parameters, while
the third found no differences with TUNEL, but only with
SCSA.
Comet Assay
Just three studies to date have used the alkaline Comet assay.
All were performed on small caseloads and found more sperm
damage, expressed as the percentage of cells with DNA forming a
comet pattern, in patients than in controls (Table 1). O’Donovan
investigated chromatin integrity pre- and post-therapy in various
neoplastic diseases, including testicular cancer (122). This was a
pilot study on a small caseload of cancer patients, including TC
and fertile men. The author found a higher level of sperm DNA
fragmentation in TC patients than in the controls. This finding
was confirmed by O’Flaherty et al. in patients with advanced
testicular cancer, for whom semen phenotype, hormone profile
and genome integrity were investigated (126). The authors
found impaired semen parameters (sperm concentration, normal
forms, and motility), an elevated FSH serum concentration
and elevated sperm DNA damage in the TC patients in
comparison with the control group of healthy volunteers.
More recently, Kumar et al. detected increased sperm DNA
damage in 19 testicular cancers patients vs. 20 semen donors
with both alkaline and neutral COMET, with higher levels
of sperm DNA fragmentation in TC patients with abnormal
semen parameters (104). In particular, under neutral conditions,
the Authors reported a significant difference in DNA DSBs
in men presenting with testicular cancer compared to fertile
donors.
In summary, the literature comprises 17 papers that used
various methods to evaluate sperm DNA integrity post-
orchiectomy and pre-therapy in testicular cancer patients.
Three used TUNEL only, eight SCSA only and three Comet
assay only, while three used both SCSA and TUNEL to
investigate the same caseload. Eleven studies found a difference
in sperm DNA damage between TC patients and controls
using one or two methods, five found no such difference
while just one found different results with different methods
(Table 1).
These studies have various limitations, above all the limited
caseloads and use of different control groups, which could
affect the comparison of the cases and controls. The use
of normozoospermic or fertile subjects as the control group
should undoubtedly produce a low percentage of sperm DNA
fragmentation, while a control group of unselected subjects
from the general population might have a slightly higher DFI.
Furthermore, not all studies reported age (an important factor
associated with chromatin fragmentation), histotype or clinical
stage, and many did not report the clinical features. It was
therefore not possible to perform a multivariate analysis to
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identify the various parameters that might affect chromatin
integrity.
Most of the studies cited in this section found elevated
sperm DNA damage in TC patients. This could be due to
a maturation defect during spermatogenesis in the remaining
testicle after orchiectomy, but also to the impact of stress factors,
abnormal hormone production (oestrogens, human chorionic
gonadotropin) or other factors linked to the development of
testicular dysplasia (70, 101, 127). Testicular cancer can in fact
be hormonally active, with the production of β-human chorionic
gonadotropin (βhCG) and α fetoprotein (AFP), and has both
local and systemic effects, including temperature changes and
metabolic effects (128). Carcinogenesis may result in a systemic
inflammatory state and the secretion of metabolically active
cytokines can lead to damage to the germinal epithelium.
Cytokines such as interleukin 1, interleukin 6, tumor necrosis
factor α, and interferon γ may affect the hypothalamic-pituitary-
gonadal axis (128, 129). Finally, cancer can itself be associated
with malnourishment, leading to deficiencies in the vitamins and
trace elements needed for optimal gonadal function, as well as
psychological issues such as anxiety and depression. For these
reasons, cancer itself may contribute to both quantitative and
qualitative impairment of spermatogenesis, even if the literature
data are contradictory.
Post-treatment
Antineoplastic therapies are an important cause of sperm DNA
damage. Interest in the toxic effects of these therapies on
embryonic development has generally focused on the mother,
while the paternal aspect has often been underestimated. Few
studies have investigated male-mediated teratogenicity (130–
132), but above all the little information that is available provides
conflicting evidence of the sperm chromatin damage induced by
these treatments.
Radiotherapy and chemotherapy have a damaging effect on
reproductive function through both cytological and molecular
effects. The negative effects include impaired spermatogenesis,
resulting in oligozoospermia or azoospermia (72, 133), and an
increase in aneuploidies for up to 18–24 months after the end
of the therapy (134–136). Most chemotherapeutic agents are
cytotoxic for cells in a given phase of the cell cycle. Furthermore,
the testicle is one of the most radiosensitive tissues and is
vulnerable to damage from both direct radiation or, more
commonly, the scattering of radiation during the treatment of
adjacent tissues (137).
While the main aim of treatment must of course be to cure
the cancer itself, the future quality of life of TC patients must not
be overlooked, given the now excellent survival rates. In young
adults, it is important to evaluate any reproductive problems
that might arise following treatment; in particular the study of
sperm chromatin integrity, which could be an infertility factor
or even be associated with genome instability, with consequent
repercussions for any offspring.
The introduction of ICSI has significantly improved the
opportunity for paternity in TC patients. However, there is
a concern that it might increase the risk of transmitting
defective paternal genomes to the offspring. For this reason,
data concerning pre- and post-treatment sperm chromatin
integrity in cancer patients, and especially TC patients, would
have significant translational relevance in the management
of these patients, as they could be provided with adequate
counseling on their future reproductive chances. Literature
reports of the impact of antineoplastic treatments give conflicting
results, due to the small caseloads, the different treatments
investigated and above all the different methods used to
study sperm DNA damage. For this reason, as in the section
above, we will present the data according to the method
used.
SCSA
The impact of cancer treatment on spermDNA integrity has been
investigated by SCSA in 7 longitudinal studies (Table 2). There
is general accordance among these studies about the negative
impact of radiotherapy (43, 114, 115, 118, 121). Stahl et al.
reported a significant but transient increase in DFI in the first
2 years after radiotherapy, which normalized 3–5 years after
the end of the treatment (114), confirming these data in a later
study with a larger caseload (115). According to Smit et al.
RT has a higher impact on DFI than CT alone; after a follow-
up of 0.5–3.3 years (median 1.1) this study found a significant
increase in DFI in patients who had undergone RT or RT+CH
compared to those who underwent chemotherapy alone (118).
A multicentre study with 24 months’ post-treatment follow-up
found reduced chromatin compaction 6 months after the end
of radiotherapy (121). Paoli et al. confirmed these observations
in a larger caseload, reporting that RT-induced DNA damage
increased up to 6months post-RT, with a subsequent reduction at
12 and 24 months (43). Evidence of the effects of chemotherapy
is more contradictory. Several studies did not find any differences
in DNA damage post-chemotherapy (116, 118, 121). Others
even found an improvement in sperm chromatin integrity: in
2004 and 2006, Stahl et al. reported that patients undergoing
1–2 chemotherapy cycles had a significant reduction in DFI at
6 and 12–24 months from the baseline, while advanced stage
patients treated with more than two chemotherapy cycles showed
a reduction in DFI 5 years after the end of the treatment
(114, 115). The authors interpret this surprising result as a
consequence of germ cell vulnerability to chemotherapy, thus
causing the prevalent elimination of spermatogenic cells with
DNA damage. In other words, chemotherapy could induce the
removal of a subpopulation of abnormal germ cells. In contrast,
in a small caseload of patients with advanced testicular cancer
after orchiectomy, O’Flaherty et al. reported higher DNA damage
and lower chromatin compaction prior to therapy, persisting
for the entire follow-up period, in comparison with controls
(119). Paoli et al. whose results in relation to radiotherapy are
reported above, also found increased CT-induced DNA damage
at 6 months with a more marked reduction than seen with RT at
12 and 24 months post-therapy, indicating a clear improvement
in the chromatin profile at these time points (43). Their data
also indicated that sperm chromatin damage was not age- or
histotype-dependent, but was more marked in advanced stages
of TC and was also influenced by the type and intensity of
treatment.
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TABLE 2 | Post-treatment sperm DNA quality in testicular cancer patients subdivided by method used.
References N.
TC pts
Follow-up Treatment DNA integrity
SCSA
Stahl et al. (114) 74 0, 6, 12, 24, 36, and 60
months
Chemo- and
Radiotherapy
RT: increased DFI up to 2 years post-treatment;
normalization after 3–5 years
CH: reduced DFI up to 5 years post-treatment
Stahl et al. (115) 96 0, 6, 12, 24, 36, and 60
months
Chemo- and
Radiotherapy
RT: increased DFI up to 2 years post-treatment;
normalization after 3–5 years
CH: reduced DFI up to 5 years post-treatment
Stahl et al. (116) 58 Mean 3 years Chemo- and
Radiotherapy
No differences in DFI pre- and post-
treatment—DNA not affected by treatment
Smit et al. (118) 52 Range 0.5 to 3.3 years Chemo- and
Radiotherapy
RT: increased DFI against CH (mean 1.1 years)
O’Flaherty et al.
(119)
16 0, 6, 12, 18, and 24
months
Chemotherapy CH: increase in SD DFI and HDS inTC patients up
to 24 months post-therapy.
Bujan et al. (121) 53 3, 6, 12, and 24
months
Chemo- and
Radiotherapy
RT: reduced chromatin compaction to T6 post RT
CH: no DFI variation pre- and post-CH
Paoli et al. (43) 254 3, 6, 9, 12, and 24
months
Chemo- and
Radiotherapy
RT: increased DFI at 3 and 6 months, less marked
reduction at 12 and 24 against CH
CH: increased DFI at 3 and 6 months and reduction
at 12–24 months
TUNEL
Stahl et al. (115) 96 0, 6, 12, 24, 36, and 60
months
Chemo- and
Radiotherapy
RT: increased DFI up to 2 years post- treatment;
normalization after 3–5 years
CH: reduced DFI up to 5 years post-treatment
Spermon et al.
(123)
22 Range 18.4–84.8
months
Chemotherapy Chromatin condensation improved after treatment
DNA fragmentation not reduced after CH
Bujan et al. (121) 53 3, 6, 12, and 24
months
Chemo- and
Radiotherapy
No change in sperm DNA fragmentation pre- and
post-treatment
Ghezzi et al. (138) 212 0, 12, 24 months 100 BEP
54 CARB
58 surveillance
BEP: at 12 and 24 months increased post therapy
DNA damage both vs. baseline and vs. CARB.
COMET
O’Donovan (122) 13 0, 3, 6, 12 months Various antineoplastic
agents
Reduced percentage of intact sperm DNA and
chromatin condensation
O’Flaherty et al.
(126)
16 0, 6, 12, 18, and 24
months
Chemotherapy Increased sperm DNA fragmentation 6 months
post-treatment against T0, remaining elevated up to
18–24 months
RT, radiotherapy; CH, chemotherapy; BEP, Bleomycin, etoposide, cisplatin; CARB, carboplatin.
TUNEL
Several studies used TUNEL to investigate the impact of
chemotherapy and radiotherapy on TC patients (Table 2).
Stahl et al. confirmed the results they had seen with SCSA,
finding increased sperm DNA damage for 2 years post-RT with
both methods, thus indicating a correlation between the two
(115). Bujan et al. did not find any increased fragmentation
after CT or RT (121). Spermon et al. who investigated the
effects of 4 cycles of BEP in a small caseload of TC patients
against normozoospermic subjects after a mean of 48.2 months,
achieved similar results (123). These authors did not find
any difference between sperm DNA fragmentation pre- and
post-chemotherapy, but only against controls. Although sperm
nuclear quality did not reach normal levels, semen samples did
show improved chromatin condensation. In contrast, Ghezzi
et al. compared patients treated with BEP, carboplatin or
under surveillance alone, finding that BEP caused significantly
more DNA damage than one cycle carboplatin. This damage
was still detectable in BEP patients after 24 months of
follow up when compared to baseline values. This seems
to reflect the fact that more intensive chemotherapies might
have higher influence on DNA integrity and for longer
time (138).
Comet Assay
In 2005, O’Donovan evaluated chromatin integrity pre- and post-
antineoplastic therapy in various neoplastic diseases including
testicular cancer (122). This was a pilot study on a small caseload,
of whom just 13 had TC. There was a lower percentage of
intact sperm DNA (percentage head DNA intact) and chromatin
condensation after treatment in patients than in the controls.
O’Flaherty et al. obtained different results in a study of 16
post-orchiectomy TC patients who underwent BEP compared
to healthy male volunteers (126). This longitudinal study found
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that chemotherapy has a negative impact in testicular cancer
patients, with increased sperm DNA fragmentation 6 months
after the end of treatment in comparison with the baseline;
this value was still raised at 18–24 months. This study thus
demonstrated that chemotherapy can induce long-lasting DNA
damage.
In summary, a total of 11 papers used various methods
to evaluate the impact of chemo- and radiotherapy on sperm
DNA integrity in testicular cancer patients. Some of these
used more than one method (Table 2), with 5 using SCSA, 2
TUNEL, 2 Comet and 2 studies used both SCSA and TUNEL
to investigate the same caseload. We identified just one paper
which did not find any sperm DNA damage in TC patients
after chemo- or radiotherapy, but the author himself suggested
that the high inter-subject variation in the impact of the
antineoplastic treatment on chromatin integrity could affect the
results. Furthermore, the median post-therapy observation time
was about 3 years in this study (range 1–20 years) and the lack
of information on DNA integrity shortly after treatment could
cause the real impact of the therapies to be underestimated
(116). In contrast, most studies found sperm DNA to be more
sensitive to radiotherapy, which induces transient damage from 6
months after the end of the treatment but normalizes within 2–5
years. In fact, radiation induces material ionization both directly,
through excitation of the atoms making up the DNA molecule,
and indirectly, through its interaction with non-DNA molecules,
which induce the ionization of the genetic material by emitting
secondary electrons (95, 139).
Evidence for the genotoxic effect of chemotherapy on sperm is
less clear-cut than that for radiotherapy. Many chemotherapeutic
drugs penetrate the Sertoli cell barrier and damage germ cells.
Type B spermatogonia, which proliferate actively, are extremely
susceptible to cytotoxic agents; chemically stable DNA adducts
produced in the testicles can persist, inducing DNA strand
breakage during the spermatogenic process. However, type A
spermatogonia, which have little mitotic activity, are less affected
and could survive polychemotherapy if threshold cumulative
cytostatic doses are not surpassed (140).
Two studies found reduced damage after chemotherapy (114,
115), suggesting that spermatogonia with abnormal chromatin
arising from defective DNA repair mechanisms might be more
sensitive to chemotherapy (115). However, it should be stressed
that these studies involved relatively small caseloads, especially
after stratification by time since end of treatment and by type of
antineoplastic treatment. Other studies found that chemotherapy
had a negative impact on the sperm chromatin profile lasting
up to 2 years after the end of the therapy. Various components
of the chromatin structure may be modified by different
chemotherapeutic agents, thus affecting not only fragmentation
but also chromatin compaction (119). The different components
of the chromatinmay thus take different times to be repaired after
chemotherapy and the extent of sperm DNA damage may also
differ. It should also be noted that studies evaluating pre- and
post-therapy chromatin integrity are highly heterogeneous and
the results could be affected not only by the small caseloads but
also by the different methods used. TUNEL and alkaline Comet
measure the number of double or single DNA strand breaks,
while SCSA provides an indirect measure of DNA damage.
The different recovery times could also depend on the different
follow-up times used in the various studies, given that they did
not all analyse samples at the same times. Furthermore, the
literature analyzed to date reveals that sperm chromatin damage
is not age- or histotype-dependent, but appears more marked in
advanced stages of TC as well as being influenced by the type and
intensity of treatment. This could explain the divergent results on
the impact of chemotherapy on sperm DNA integrity obtained
by the different authors discussed above, and more studies are
needed to provide conclusive evidence.
PATERNITY AND TESTICULAR CANCER
The paternity of TC survivors is a particularly interesting topic.
These patients often ask about their chance of fatherhood,
the teratogenicity of their treatment or the risk of TC in
their offspring. Around 40% of patients pre-diagnosis and
50% post-diagnosis want children (141). For this reason,
the cryopreservation of semen and/or testicular tissue is of
fundamental importance in the clinical management of this
disease (142, 143). Various antineoplastic treatments can induce
mutagenic effects in both somatic cells and male germ cells at
various stages of maturation. However, we are as yet unable
to predict the extent of any genomic damage, the potential
teratogenic effect and the long term effects on fertility and
offspring outcome caused by these treatments. Studies in mouse
models have shown that cisplatin induces chromatid breaks
and fragments in spermatocytes and spermatogonia immediately
after treatment, whereas conflicting results have been reported in
relation to diploidy and disomy in treated patients (135, 144–
146). The injurious effect of chemotherapy on offspring may
be related to abnormal sperm chromatin structure. Proteome
studies (147) found up-regulation of histones and a significant
decrease in protamine in the mouse sperm head, while other
studies found increased methylation in drug-treated animals
(148, 149).
Although sperm chromatin damage has been observed to
a greater or lesser extent in TC patients, it does not seem
to be invariably correlated with a diagnosis of infertility in
the survivors of this disease. Sperm DNA mutations seem
to be associated with a lower fertility than found in the
healthy population and an increased risk of early abortion.
However, there is a lack of prospective studies in the literature
investigating the correlation between TC-induced sperm DNA
damage and reproductive outcome. This would be extremely
useful information, especially as the ever-increasing use of ART
could in theory give rise to a greater risk of selecting sperm with
damaged DNA. The available data on the in vivo and in vitro
reproductive capacity of TC survivors and the known effects on
offspring are discussed below.
Data From National Registers
Population studies, mainly originating from north European
national registers, suggest that the fertility of cancer survivors
is lower than that of the general population. Fifty percent of
post-cancer patients presented primary infertility (150). Fossa
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et al. reported that on average, cancer patients had conceived at
least one child 3–4.5 years after the end of the treatment (151).
In comparison with the general population, testicular cancer
survivors had a 33% lower probability of having a child within 5
years after diagnosis and 20% lower after more than 5 years (152);
these data were confirmed by later studies (150, 153–155).
The most recent observation comes from a study by Gunnes
et al. who found in data from Norwegian registers a reduced
probability of fatherhood (HR 0.77) and greater use of ART in
TC survivors than in the control population (155). It should be
stressed that these population studies have limitations. Studies
based on caseloads from national registers often lack details
of the type of treatment, the physical condition of individual
patients, the physical condition of neonates after the first day
of life and information on the female partner such as maternal
age, parity, smoking, and behavior during pregnancy and, above
all, many of these studies do not specify if pregnancy occurred
naturally or following ART. On the whole, they demonstrate that
male cancer survivors, including TC survivors, do have a chance
of achieving fatherhood through natural conception or assisted
reproduction despite the damage induced by the antineoplastic
treatment, even if this chance is lower than in the general
population.
Effects on Offspring
The incidence of any effects in the offspring of fathers treated
with antineoplastic therapies was not always investigated by
the various studies and the evidence in the literature is highly
contradictory. Unlike in children born tomothers with a previous
diagnosis of cancer, some Danish multicentre and register
studies did not find any increased risk of congenital or genetic
abnormalities in the children of male cancer survivors treated
with chemotherapy or radiotherapy (151, 152, 156–158) and
did not find any increased risk of perinatal death, low birth
weight or preterm birth (155). In contrast, Magelssen et al. found
an increased incidence of congenital abnormalities in firstborn
infants fathered after the cancer diagnosis, regardless of whether
or not ART was used (153). The abnormalities reported in this
study were observed after various types of treatment and up
to 15–20 years after diagnosis, even if they were not correlated
with any specific antineoplastic treatment. Data fromDanish and
Swedish registers also found that children with a paternal history
of cancer had a significantly increased risk of any congenital
abnormality (RR = 1.12, CI 95% 1.02–1.24; p = 0.018), and
especially major congenital abnormalities (RR = 1.17, CI 95%
1.05–1.31; p = 0.004), regardless of how they were conceived
(natural, ART, cryopreserved, or fresh semen), than the children
of healthy controls (159). This risk was higher among children
born within 2 years of their father’s cancer diagnosis, suggesting
that the cause is the transient effect of treatment on sperm DNA
quality. In this case too, interpretation of the data is limited by
the nature of the registers; although they report events in very
large caseloads, they cannot unequivocally trace such events back
to the impact of previous antineoplastic chemo- or radiotherapy.
Given that measurable sperm nuclear damage has been
demonstrated for both RT and CT, especially in the first 12–
24 months after the end of treatment, it is reasonable to
suppose that malformations and early abortions occurring in
this time period can probably be attributed to the effects of
the treatment on sperm DNA. This aspect should thus be
discussed openly with the patient, to enable the protection
of the patient’s future fertility through cryopreservation of
semen or testicular tissue before beginning any treatment
(Table 3A).
TABLE 3A | Summary of available data from national registers/population studies on fertility in testicular cancer survivors.
Reference Total male
cancer
patients
Fatherhood
after
diagnosis
Total use of
ART
Testicular
cancer patients
(%)
Children after TC
diagnosis (%)
Probability of
fatherhood
Risk of major
congenital
malformations in
offspring
Fossa et al. (151) 5,173 972 N/A 1854 (35.8%) 429 (23.1%) 8 and 14% after 5
and 10 years
No increased risk
Syse et al. (152) 7,127 1,731 N/A 567 (7.9%) N/A OR 0.8 after 5
yearsb
N/A
Madanat et al.
(150)
11,985 1,834 N/A 1,273 (10.6%) 366 (28.7%) RR 0.57 for first
childc
N/A
Magelssen et al.
(153)
463 142 8.4% 211 (45.6%) 72 (34.1%) 42% 10 years
post-diagnosisd
27 cases reporteda
OR = 1.8b
Stahl et al. (159) N/A 8,670 5.9% N/A N/A N/A Increased risk RR =
1.17a
Stensheim et al.
(154)
11,451 2,618 2.3% 3,511 (30.7%) 1,081 (30.8%) HR 0.74a N/A
Signorello et al.
(156)
1,128e 1,128e N/A None N/A N/A 36 cases reported.
no increased riska
Winther et al. (157) 722 722e N/A N/A N/A N/A No increased riska
Stensheim et al.
(158)
2,087 2,087e 2.6% 805 (38.6%) N/A N/A No increased riska
Gunnes et al. (155) 2,687 1,087 3.0% 734 (27.3%) 349 (47.5%) HR 0.77a No increased riska
Frontiers in Endocrinology | www.frontiersin.org 9 September 2018 | Volume 9 | Article 506
Paoli et al. Sperm DNA and Testicular Cancer
T
A
B
L
E
3
B
|
S
u
m
m
a
ry
o
f
a
va
ila
b
le
d
a
ta
fr
o
m
c
o
h
o
rt
st
u
d
ie
s
o
n
n
a
tu
ra
la
n
d
A
R
T
fe
rt
ili
ty
in
te
st
ic
u
la
r
c
a
n
c
e
r
su
rv
iv
o
rs
.
R
e
fe
re
n
c
e
To
ta
l
m
a
le
c
a
n
c
e
r
p
a
ti
e
n
ts
To
ta
l
u
s
e
o
f
A
R
T
Te
s
ti
c
u
la
r
c
a
n
c
e
r
p
a
ti
e
n
ts
C
h
il
d
re
n
b
e
fo
re
T
C
d
ia
g
n
o
s
is
(%
)
C
h
il
d
re
n
a
ft
e
r
T
C
d
ia
g
n
o
s
is
(%
)
C
h
il
d
re
n
a
ft
e
r
A
R
T
in
T
C
p
a
ti
e
n
ts
T
im
e
to
fi
rs
t
c
h
il
d
a
ft
e
r
T
C
d
ia
g
n
o
s
is
A
d
v
e
rs
e
e
v
e
n
ts
in
o
ff
s
p
ri
n
g
H
a
rt
m
a
n
n
e
t
a
l.
(1
6
0
)
9
8
N
/A
9
8
3
9
(3
9
.8
%
)
2
1
(2
1
.4
%
)
N
/A
M
e
d
ia
n
5
4
m
o
n
th
s
a
ft
e
r
tr
e
a
tm
e
n
t
N
o
n
e
re
p
o
rt
e
d
,
3
m
is
c
a
rr
ia
g
e
s
K
e
lle
h
e
r
e
t
a
l.
(1
6
8
)
9
0
1
6
4
(7
.7
%
)
3
4
8
N
/A
N
/A
N
/A
M
e
d
ia
n
3
6
m
o
n
th
s
3
c
a
se
s
re
p
o
rt
e
d
a
S
p
e
rm
o
n
e
t
a
l.
( 1
6
2
)
2
2
6
2
2
6
9
3
/1
2
0
(7
7
.5
%
)f
5
4
/8
8
(6
1
.4
%
)f
8
/8
8
(1
4
.8
%
)
M
e
d
ia
n
4
6
m
o
n
th
s
N
o
n
e
re
p
o
rt
e
d
,
7
m
is
c
a
rr
ia
g
e
s
A
g
a
rw
a
le
t
a
l.
(1
7
0
)
3
1
g
1
2
(3
8
.7
%
)
1
1
N
/A
8
(7
2
.7
%
)
6
(5
4
.5
%
)
N
/A
N
o
n
e
re
p
o
rt
e
d
,
4
m
is
c
a
rr
ia
g
e
sa
C
h
u
n
g
e
t
a
l.
( 1
6
9
)
1
6
4
g
6
/1
2
7
(4
.7
%
)f
4
2
N
/A
N
/A
1
/3
(3
3
.3
%
)f
N
/A
N
/A
H
u
yg
h
e
e
t
a
l.
(1
6
3
)
4
4
6
4
4
6
2
0
8
/2
2
8
(9
1
.2
%
)f
1
1
0
/1
6
4
(6
7
.1
%
)f
7
/1
6
4
(6
.4
%
)
M
e
a
n
4
.8
±
3
.0
ye
a
rs
N
/A
N
a
le
sn
ik
e
t
a
l.
( 1
6
4
)
7
3
7
3
N
/A
6
/1
1
(5
4
%
)f
N
/A
N
/A
N
o
n
e
re
p
o
rt
e
d
,
1
m
is
c
a
rr
ia
g
e
S
c
h
m
id
t
e
t
a
l.
(1
7
1
)
6
7
3
4
(5
0
.7
%
)
3
4
N
/A
N
/A
N
/A
N
/A
7
m
is
c
a
rr
ia
g
e
s,
2
e
c
to
p
ic
a
M
a
g
e
ls
se
n
e
t
a
l.
(1
7
2
)
1
,3
8
8
1
,3
8
8
6
9
3
(4
9
.9
%
)
5
1
3
(3
9
.0
%
)h
2
9
(2
.1
%
)
N
/A
2
sp
o
n
ta
n
e
o
u
s
a
b
o
rt
io
n
s
a
ft
e
r
A
R
T
G
ira
so
le
e
t
a
l.
( 1
6
1
)
1
2
9
1
2
9
6
5
(5
0
.4
%
)
2
8
(2
1
.7
%
)
2
(7
.1
%
)
N
/A
N
/A
H
o
u
rv
itz
e
t
a
l.
(1
7
4
)
1
1
8
1
1
8
(1
0
0
%
)
4
7
N
/A
N
/A
N
/A
N
/A
1
1
sp
o
n
ta
n
e
o
u
s
a
b
o
rt
io
n
s
va
n
C
a
st
e
re
n
e
t
a
l.
( 1
7
3
)
6
2
9
1
8
/3
7
(4
8
.7
%
)f
2
3
6
N
/A
N
/A
N
/A
N
/A
2
e
a
rly
a
b
o
rt
io
n
s
a
ft
e
r
A
R
T
a
C
h
ra
e
t
a
l.
(1
7
5
)
6
1
9
2
8
(4
.5
%
)
2
7
0
N
/A
N
/A
N
/A
M
e
d
ia
n
1
8
m
o
n
th
s
N
/A
P
in
g
e
t
a
l.
( 1
7
6
)
1
5
4
8
i
2
/3
0
(6
.7
%
)
2
1
N
/A
1
/3
0
(3
.3
%
)
1
/3
0
(3
.3
%
)
N
/A
N
/A
M
a
to
s
e
t
a
l.
(1
4
1
)
2
9
7
2
9
7
9
8
/1
1
9
(8
2
.4
%
)f
7
4
/1
5
0
(4
9
.3
%
)f
N
/A
M
e
d
ia
n
1
2
ye
a
rs
fr
o
m
d
ia
g
n
o
si
s
N
/A
F
re
o
u
r
e
t
a
l.
( 1
7
7
)
1
0
4
2
8
2
(7
.9
%
)
4
3
8
N
/A
2
/2
7
(7
.4
%
)f
2
/2
7
(7
.4
%
)f
N
/A
N
o
n
e
re
p
o
rt
e
d
B
iz
e
t
e
t
a
l.
(1
7
8
)
B
o
tc
h
a
n
e
t
a
l.
(1
7
9
)
6
8
2
2
7
/7
0
(3
8
.6
%
)f
2
1
6
N
/A
N
/A
1
3
/1
8
(7
2
.2
%
)f
6
3
%
tr
ie
d
A
R
T
w
ith
in
3
ye
a
rs
N
o
n
e
re
p
o
rt
e
d
,
4
a
b
o
rt
io
n
s,
3
e
xt
ra
-u
te
rin
e
M
o
ln
a
r
e
t
a
l.
( 1
8
2
)
5
2
5
2
N
/A
1
6
(3
0
.8
%
)
4
/7
(5
7
%
)f
N
/A
6
m
is
c
a
rr
ia
g
e
s
re
p
o
rt
e
d
P
in
g
e
t
a
l.
(1
6
6
)
1
1
7
1
1
7
2
1
/6
9
(3
0
.4
%
)f
3
5
/7
3
(4
7
.9
%
)f
1
9
/7
3
(2
6
.0
%
)f
N
/A
N
o
n
e
re
p
o
rt
e
d
,
4
m
is
c
a
rr
ia
g
e
s
Z
a
ko
va
e
t
a
l.
( 1
8
1
)
5
2
3
1
6
/3
4
(4
7
%
)f
5
2
3
N
/A
N
/A
1
6
/3
4
(4
7
%
)f
A
R
T
a
b
o
u
t
1
8
m
o
n
th
s
a
ft
e
r
se
m
e
n
c
ry
o
p
re
se
rv
a
tio
n
N
/A
G
a
rc
ia
e
t
a
l.
(1
8
4
)
2
7
2
1
4
/2
9
(4
8
.2
%
)f
5
2
N
/A
N
/A
9
(1
7
.3
%
)f
N
/A
N
/A
a
A
ll
ty
p
e
s
o
f
c
a
n
c
e
r.
b
C
o
m
p
a
re
d
to
c
o
n
tr
o
lp
o
p
u
la
ti
o
n
.
c
C
o
m
p
a
re
d
to
s
ib
lin
g
s
w
it
h
o
u
t
c
a
n
c
e
r.
d
Te
s
ti
c
u
la
r
c
a
n
c
e
rs
.
e
O
n
ly
p
a
ti
e
n
ts
w
it
h
c
h
ild
re
n
w
e
re
s
e
le
c
te
d
.
f F
a
th
e
rh
o
o
d
a
c
h
ie
ve
d
/p
a
ti
e
n
ts
w
h
o
tr
ie
d
to
c
o
n
c
e
iv
e
.
g
O
n
ly
p
a
ti
e
n
ts
w
h
o
c
ry
o
p
re
s
e
rv
e
d
th
e
ir
s
e
m
e
n
.
h
P
a
ti
e
n
ts
w
it
h
c
h
ild
re
n
2
0
ye
a
rs
a
ft
e
r
d
ia
g
n
o
s
is
.
i O
n
ly
3
0
c
a
n
c
e
r
p
a
ti
e
n
ts
.
Frontiers in Endocrinology | www.frontiersin.org 10 September 2018 | Volume 9 | Article 506
Paoli et al. Sperm DNA and Testicular Cancer
Data on Natural Fertility
Various studies have investigated natural fertility pre- and post-
treatment in TC survivors, with a broad range of results. Some
studies reported that 39 and 40% of TC patients achieved
paternity through natural means before starting any treatment
(160, 161) while others found a much higher pre-therapy fertility
rate of between 77.5 and 91% (141, 162, 163). This suggests
that, at least in a subgroup of patients, fertility may already be
compromised at the baseline.
After treatment, 52% of TC patients fathered a child, most
within 1 year (161). A natural pregnancy was achieved by
64% of seminoma patients treated with radiotherapy with
testicular shielding (164), although other authors (163) found
that radiotherapy was more harmful than chemotherapy,
and cumulative conception rates for patients treated with
radiotherapy were significantly lower than the rates for patients
treated with chemotherapy. Brydoy et al. found that after 2–
4 cisplatin-based chemotherapy cycles around 80% (85/106)
of TC patients fathered a child by natural conception and
the probability of fatherhood was inversely correlated with the
number of cycles (165). However, Matos et al. reported lower
natural post-therapy fertility rates, at 50% (74/150) (141). In Ping
et al.’s study, 21.9% (16/73) had conceived naturally and 26.0%
(19/73) by ART (166). The literature thus contains a wide range
of data, probably due to differences in irradiation procedures and
chemotherapy regimens; for this reason, as well as differences in
the patient cohorts and the aims of each study, the comparison of
different studies is difficult.
Data on ART
TC survivors seem to resort to ART more frequently than
the general population, with around three times the number
of pregnancies resulting from ART (154, 155). Lass et al.
hypothesized that the improvement in treatments and in the life
expectancy of cancer patients would lead to a greater number
of patients being offered the chance of semen cryopreservation
for use in ART (167). Kelleher et al. studied 833 patients with
different types of cancer (37% with TC) who had cryopreserved
their semen, finding that 7.7% (64 patients) had used it for
various assisted reproduction techniques, achieving a total of 29
pregnancies (168). In contrast, Chung et al., who also studied
patients with different types of cancer (including 42 with TC),
reported that just 4.7% (6/127 patients) had used cryopreserved
semen, resulting in two pregnancies, one by IVF and one using
ICSI (169). Agarwal et al. (170) and Schmidt et al. (171) found
higher success rates with ART, with respectively 4/9 TC patients
and 34/67 cancer patients (predominantly TC and Hodgkin’s
disease) achieving at least one child born following ART with
fresh or frozen semen. Magelssen et al. reported that 14/29 TC
patients had conceived at least one healthy child, while two
pregnancies had ended in spontaneous abortion (172). Later
studies found excellent pregnancy rates (above 50%) in the
partners of patients who had undergone semen cryopreservation
for various cancers, especially TC (173, 174). In contrast, Crha
et al. reported a somewhat lower success rate, at 29.5% (175).
Ping et al. (176), Freour et al. (177), and Bizet et al. (178)
all studied large caseloads of post-treatment cancer patients, but
these included few TC patients. These authors reported a lower
pregnancy rate following ART. Botchan et al. reported the use
of ART in 70/682 patients who had cryobanked semen prior
to cancer treatment, achieving 36 to-term pregnancies (179).
The previously cited study by Ping et al. (166) analyzed the
reproductive outcome of 117 TC patients post-treatment, finding
that 19 (26%) of the 73 patients attempting fatherhood had
been successful through ART with fresh semen (11 patients)
or cryobanked semen (8 patients), similar to the results of a
later study by Gil et al. (180). Zakova et al. (181) found a
higher pregnancy rate, at 47% (16/34 patients), and better results
were also reported by Molnar et al. (182) (57%; 4/7 patients).
Sonnenburg et al. (183) reported live births with ART in 82%
(9/11) of the couples that used banked semen, while Garcia
et al. (184) found live birth rates in cancer patients and cancer-
free infertile patients similar to the previous studies (Table 3B).
Finally, in a recent systematic review, Ferrari et al. (185) reported
that, with a relatively low use (8%) of cryobanked semen samples,
the cumulative percentage of couples achieving pregnancy by
ART was around 49%.
All these studies show that ART is a valid option for patients
who are unable to achieve a natural pregnancy. Although some
authors have hypothesized an additional risk of adverse effects in
the offspring after ART in these patients, this suspicion must be
confirmed by further study (186). The limitations of these studies
include the diversity of their caseloads and the different ART
methods used, which could influence the published results. In
fact, although some caseloads were relatively large, they generally
included survivors of different types of cancer in different organs,
which could affect the reproductive axis (and hence fertility)
in different ways. Furthermore, it is not always possible to
extrapolate the data for TC patients alone, who in some cases
amount to just a few individuals. Finally, since the oocyte has an
essential role in maintaining genome integrity and in reducing
the transmission of new mutations and chromosomal structural
aberrations to the offspring (187–189), another confounding
factor is that the clinical data of the female partners, which could
influence the outcome of ART, is often unreported.
CONCLUSIONS
Pre-therapy Sperm DNA Damage
Most papers found a high level of sperm DNA damage in TC
patients in comparison with healthy, fertile controls but no
significant difference between TC patients and infertile patients.
However, it should be stressed that these studies have various
limitations which affect the comparison of the cases and controls
and make it difficult to interpret the results.
Post-therapy Sperm DNA Damage
Some literature reports of treatment-induced sperm DNA
changes indicated increased chromatin damage for up to 2 years
after the end of the treatment. Such damage is more marked in
advanced stages, suggesting that sperm from patients with more
invasive TC is more vulnerable to antineoplastic treatments.
Post-therapy DNA damage is also influenced by the treatment
type and dose. The spermatogenic line seems to be more sensitive
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TABLE 4 | Summary of evidence and future suggestions.
Sperm DNA
damage
• Higher pre-treatment sperm DNA damage in TC patients in comparison with healthy, fertile controls but without significant differences
between TC and infertile patients.
• Sperm DNA damage detected for up to 2 years after the end of the treatment. Such damage is more marked in advanced stages and is
also influenced by the treatment type and dose.
Fatherhood
chance
• Population studies report a reduced (about 25% lower) reproductive capacity in cancer survivors than in the general population, regardless
of the tumor type.
• Studies of cohorts of TC survivors report a wide range of natural paternity rates (20–80%). However, due to heterogeneity, these data are
difficult to evaluate.
• TC survivors resort to ART more frequently than the general population.
• ART, including the use of cryobanked sperm, has a success rate of around 50%, especially with more advanced techniques (ICSI).
Congenital
anomalies
• Most authors did not find any increased risk of major anomalies (congenital or genetic abnormalities, perinatal death, low birth weight,
preterm birth) in the children of male cancer survivors treated with chemotherapy or radiotherapy.
• A few authors found an increased risk of congenital abnormalities, at their peak in children born within 2 years of their father’s cancer
diagnosis.
• Several authors reported miscarriages, but did not compare rates against cancer-free patients.
Future
suggestions
• Negative effects on sperm DNA structure which may affect the reproductive capacity of TC patients make adequate counseling essential
before beginning any potentially genotoxic treatment.
• Clinicians should also discuss post-treatment fertility as well as sperm cryopreservation strategies and the possible future use of ART.
• More high quality studies with adequate follow ups are needed to confirm previous observations of sperm DNA damage.
• Further studies investigating the extent of this damage might identify the time needed for the germ cell line to repair nuclear damage
and thus produce gametes with a reduced risk for the offspring.
to radiotherapy than to chemotherapy. However, the various
studies do identify negative effects of both TC and its treatments
on the DNA structure which could affect the reproductive
capacity of TC patients.
All these aspects should be discussed with the patient during
counseling before beginning any potentially genotoxic treatment,
to enable the protection of the patient’s future fertility, if desired,
through cryopreservation of undamaged semen or testicular
tissue.
In any case, additional studies with a greater statistical power
are needed to confirm the effects and persistence of sperm
DNA damage. Specifically, further characterization of the type of
damage seems necessary, in order to establish more precisely its
correlation with reproductive outcomes.
Fatherhood
Population studies reveal that north European cancer survivors
have an overall reproductive capacity about 24–30% lower than
that of the general population, regardless of the tumor type. Some
studies found that TC survivors had a 33% lower probability
of having a child within 5 years after diagnosis and 20%
lower after more than 5 years. The main limitation of these
studies is that they investigate cancer registers. Although these
registers enable large caseloads to be studied, they include all
types of cancer, and it is not always possible to extrapolate
data for TC survivors alone: data pertaining to the fertility
of these subjects vary considerably according to the tumor
site. Furthermore, they do not include important information
which might influence both patient and couple fertility, such
as type of treatment, physical condition of individual patients
and of the neonates, and information on the female partner
such as maternal age, parity, smoking, and behavior during
pregnancy.
Studies of cohorts of TC survivors report conflicting evidence
in relation to natural paternity, with rates ranging from 20 to
80%. Moreover, although they demonstrate that paternity for
TC patients is possible, these studies are difficult to compare
due to their inclusion of different treatment types, age of onset,
and above all sample size. TC survivors seem to resort to ART
more frequently than the general population, with around three
times the number of pregnancies resulting from ART. In fact,
ART has increased the chance of fatherhood for these patients,
including through the use of cryobanked sperm. The studies
included in this review demonstrate a success rate of around
50%, especially with more advanced techniques (ICSI); again,
however, their analysis is limited by their different treatment
types and the inconsistent presence of data on the female
partner.
Congenital Anomalies
There are contradictory reports of the incidence of any effects
in the offspring of fathers treated with antineoplastic therapies.
Most authors did not find any increased risk of congenital
or genetic abnormalities, perinatal death, low birth weight or
preterm birth in the children of male cancer survivors treated
with chemotherapy, or radiotherapy. However, others reported
an increased risk of congenital abnormalities, at their peak in
children born within 2 years of their father’s cancer diagnosis.
This suggests that they are caused by the effect of the treatment on
sperm DNA quality, as highlighted by sperm chromatin studies
(Table 4).
In conclusion, oncofertility is a highly interesting field,
especially in TC survivors, as the marked improvement in
prognosis in recent decades has caused attention to shift
to quality of life and reproductive health. Sperm chromatin
damage associated with genome instability is the most important
reproductive side effect related to themalignancy or its treatment.
Studies investigating the extent of this damage could have a
considerable translational importance in the management of
cancer patients, as they could identify the time needed for
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the germ cell line to repair nuclear damage and thus produce
gametes with a reduced risk for the offspring. However, given
the ambiguity of the results of the studies reported in the
literature to date, further studies with a greater statistical power
are needed.
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